MLSS MILESTONE SCIENTIFIC INC.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 855683 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.9%
TTM net income YoY46.6%
TTM EPS YoY55.6%
Revenue 3-yr CAGR-1.8%
Net income 3-yr CAGR—
Margins
Gross margin70.9%
Operating margin-40.0%
Net margin-38.3%
FCF margin-16.0%
EBITDA margin-39.2%
Returns
ROE-114.7%
ROA-46.1%
ROIC (approx.)-165.6%
Asset turnover1.20x
Leverage & solvency
Liabilities / assets47.3%
Debt / equity0.00x
Current ratio2.06x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.41x
Accruals ratio-27.1%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.22M | $2.84M | $2.16M | $2.06M | $2.36M | $2.32M | $2.23M | $2.01M |
| Cost of revenue | $614,218 | $930,871 | $598,009 | $556,313 | $719,247 | $705,860 | $584,985 | $502,452 |
| Gross profit | $1.61M | $1.91M | $1.56M | $1.50M | $1.64M | $1.62M | $1.65M | $1.51M |
| R&D expense | $10,413 | $6,609 | — | $12,334 | $16,226 | $51,789 | $369,120 | $217,532 |
| SG&A expense | $2.32M | $2.95M | $2.37M | $2.55M | $2.74M | $3.03M | $3.26M | $3.33M |
| Operating income | -$746,292 | -$1.06M | -$828,083 | -$1.08M | -$1.13M | -$1.48M | -$2.00M | -$2.04M |
| Pretax income | -$747,545 | -$1.06M | -$839,853 | -$1.09M | -$1.15M | -$1.48M | -$1.99M | -$2.04M |
| Income tax | — | — | — | — | — | $0 | — | — |
| Net income | -$747,545 | -$960,581 | -$759,861 | -$1.09M | -$1.15M | -$1.48M | -$1.99M | -$2.04M |
| EBITDA | -$726,196 | -$1.04M | -$808,629 | -$1.06M | -$1.11M | -$1.47M | -$1.98M | -$2.03M |
| EPS (basic) | -0.01 | -0.01 | -0.01 | — | -0.01 | -0.02 | -0.02 | — |
| EPS (diluted) | -0.01 | -0.01 | -0.01 | — | -0.01 | -0.02 | -0.02 | — |
| Weighted avg. shares (diluted) | 93.91M | 93.13M | 85.04M | — | 82.32M | 82.05M | 81.85M | — |
| Banking | ||||||||
| Net interest income | — | — | — | — | — | $1,521 | $3,267 | $6,752 |
| Balance sheet | ||||||||
| Cash & equivalents | $1.32M | $2.07M | $1.20M | $1.11M | $1.35M | $1.27M | $2.25M | $3.26M |
| Short-term investments | — | — | — | — | — | — | — | $0 |
| Receivables | — | — | — | — | — | — | — | $475,376 |
| Inventory | $2.74M | $3.09M | $3.49M | $3.78M | $4.13M | $3.90M | $4.16M | $3.71M |
| Current assets | $6.77M | $8.12M | $7.35M | $7.48M | $8.11M | $7.63M | $8.62M | $9.29M |
| PP&E, net | $18,795 | $20,127 | $18,474 | $19,193 | $18,254 | $14,671 | $12,240 | $12,921 |
| Intangibles | $27,754 | $44,857 | $61,960 | $79,063 | $96,039 | $113,494 | $130,949 | $148,404 |
| Total assets | $6.94M | $8.35M | $7.96M | $7.81M | $8.49M | $8.05M | $9.09M | $9.80M |
| Current liabilities | $3.28M | $4.40M | $4.86M | $3.94M | $5.03M | $3.77M | $4.44M | $3.74M |
| Total liabilities | $3.29M | $4.88M | $5.68M | $4.80M | $5.94M | $4.71M | $4.63M | $3.96M |
| Shareholders' equity | $3.66M | $3.85M | $2.56M | $3.01M | $2.55M | $3.34M | $4.46M | $5.83M |
| Shares outstanding | 90.61M | 88.76M | 80.45M | 80.45M | 78.56M | 78.56M | 78.20M | 78.01M |
| Cash flow statement | ||||||||
| Operating cash flow | -$746,301 | -$585,127 | $86,842 | -$226,129 | $81,775 | -$1.76M | -$1.01M | -$1.51M |
| Capital expenditure | $1,662 | $4,139 | $1,632 | $3,116 | $6,232 | $4,472 | $1,304 | $3,528 |
| Free cash flow | -$747,963 | -$589,266 | $85,210 | -$229,245 | $75,543 | -$1.77M | -$1.01M | -$1.52M |
| Investing cash flow | -$1,662 | -$4,139 | -$1,632 | -$3,116 | -$6,232 | -$4,472 | -$1,304 | -$3,528 |
| Financing cash flow | -$3,406 | $1.46M | -$3,428 | -$3,414 | -$4,556 | $796,583 | -$2,278 | -$2,523 |
| Depreciation & amortization | $20,096 | $19,589 | $19,454 | $19,155 | $20,104 | $19,496 | $19,440 | $8,713 |
| Stock-based compensation | $99,444 | $309,578 | $256,683 | $99,168 | $363,083 | $159,678 | $330,787 | $339,852 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.